Spago Nanomedical Spago Nanomedical AB announces that the company’s application to start the clinical phase I/IIa study, Tumorad-01, with the candidate drug 177Lu-SN201 in cancer patients has been approved.
Spago Nanomedical Spago Nanomedical AB announces that the company’s application to start the clinical phase I/IIa study, Tumorad-01, with the candidate drug 177Lu-SN201 in cancer patients has been approved.